-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
-
Summary
-
EyePoint Pharmaceuticals, Inc. quarterly Deferred Tax Assets, Operating Loss Carryforwards history and growth rate from Q2 2011 to Q4 2023.
- EyePoint Pharmaceuticals, Inc. Deferred Tax Assets, Operating Loss Carryforwards for the quarter ending December 31, 2023 was $82.6M, a 6.76% decline year-over-year.
Deferred Tax Assets, Operating Loss Carryforwards, Quarterly (USD)
Deferred Tax Assets, Operating Loss Carryforwards, YoY Quarterly Growth (%)